Prior Authorization Denied? Your 2026 Appeal Playbook

A prior authorization denial isn't the end of the road — it's the start of an appeal, and appeals for GLP-1 medications succeed often enough to be worth the effort. Here's the actual playbook for 2026.

Why PAs get denied in the first place

• Missing or vague ICD-10 coding — a code like "obesity, unspecified" is far easier to reject than one paired with a specific comorbidity
• No documentation of a prior weight-management attempt, which some plans require before approving medication
• Requested medication isn't on your plan's formulary at all
• Missing BMI documentation or comorbidity evidence

The appeal playbook

1. Get the specific denial reason in writing. "Not medically necessary" is not specific enough — request the exact policy criteria that weren't met.
2. Work with your prescriber on more specific coding. A vague obesity code paired with a comorbidity code (hypertension, sleep apnea, prediabetes) tells a stronger clinical story than obesity alone.
3. Submit a formal written appeal referencing the specific plan criteria, not just a general request for reconsideration.
4. If denied again, request a peer-to-peer review between your prescriber and the plan's medical reviewer — this resolves a meaningful share of borderline cases.

If the appeal still doesn't work

A cash-pay alternative doesn't require insurance approval at all. It's a different tradeoff — predictable pricing without the PA process, weighed against the FDA-approval status of your specific medication choice.

The bottom line

Pursue the appeal — specific coding and a peer-to-peer review resolve more denials than people expect. But you don't have to wait on that process to start treatment if a cash-pay path fits your budget in the meantime.